有观点认为，硅谷AI实验室的精英群体过度强调了智能本身的作用[1]，而在医学、住房等真实世界问题中，监管和政策障碍才构成了真正的主要瓶颈[1]。以生物制药为例，临床试验耗时约七年、成本超十亿美元，是制约该领域发展的重大瓶颈[1]。同时，骨矿物质密度（BMD）作为替代终点的验证耗时12年，尽管相关数据已完全存在[1]，这反映出现行监管框架而非技术能力不足才是关键制约因素。
现实中的监管改革已显现出其强大效能。中国生物科技在过去十年从零跃升至占西方制药企业许可协议超50%[1]，这一快速增长主要源于监管改革允许更快的人体数据迭代学习[1]。相比之下，专利制度奖励新型化学物质而非新生物靶点，导致企业集中在已验证的靶点[1]，从而限制了药物研发的创新范围。AI驱动的生物公司如Chai Discovery（估值38亿美元）和Isomorphic Labs主要聚焦分子设计优化，而非扩展已验证靶点的前沿[1]。经济学家泰勒·考恩在2023年Progress Conference指出，AI能力到达的速度比其所产生的现实变化更快，GDP增长将低于预期[1]。
An analysis shared on Hacker News challenges the prevailing view within Silicon Valley's AI elite, arguing that regulatory and policy obstacles—rather than technological capabilities—represent the primary constraint on progress in fields such as medicine and housing [1]. The author contends that artificial intelligence advancement has outpaced its real-world applications, with current policy frameworks failing to leverage available computational power effectively.
In the medical sector, regulatory structures substantially impede innovation [1]. Clinical trials require approximately seven years and cost over one billion dollars, creating a significant bottleneck for pharmaceutical development [1]. Furthermore, the patent system incentivizes novel chemical compounds rather than new biological targets, concentrating corporate research efforts on already-validated targets rather than frontier exploration [1]. The validation of bone mineral density as a surrogate endpoint consumed twelve years despite complete data availability [1]. This regulatory inertia contrasts sharply with China's biotechnology sector, which surged from negligible participation to capturing over fifty percent of Western pharmaceutical licensing agreements within the past decade—a transformation driven primarily by regulatory reforms enabling faster human data iteration cycles [1].
AI-focused biotech companies, including Chai Discovery, valued at 3.8 billion dollars, and Isomorphic Labs, concentrate their efforts on molecular design optimization rather than expanding established biological targets [1]. The author supports this assessment by citing economist Tyler Cowen's remarks from the 2023 Progress Conference, noting that artificial intelligence capabilities have advanced faster than the resulting societal changes, leading to predictions of lower-than-expected GDP growth and absence of mass unemployment [1]. The disconnect between technological potential and practical implementation underscores that governance frameworks, not raw computational intelligence, represent the true limiting factor in addressing contemporary challenges.